Publication Name	World Journal of Gastroenterology
Manuscript ID	8307
Country	Italy

Received	2013-12-25 09:08
Peer-Review Started	2013-12-25 15:05
To Make the First Decision	2014-02-14 12:54
Return for Revision	2014-02-19 12:29
Revised	2014-02-25 04:50
Second Decision	2014-05-29 19:34
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-29 19:52
Articles in Press	2014-05-29 20:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-13 17:23
Publish the Manuscript Online	2014-08-29 11:57

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Topic Highlights
Article Title	Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment
Manuscript Source	Invited Manuscript
All Author List	Carlo Visco and Silvia Finotto
Funding Agency and Grant Number	Funding Agency Grant Number AViLL/AIL (Associazione Vicentina per le Leucemie, i Linfomi e il Mieloma/Associazione Italiana Leucemie) (Vicenza, Italy) Hematology Project Foundation (HPF, Fondazione Progetto Ematologia, Vicenza, Italy)
Corresponding Author	Correspondence to: Carlo Visco, MD, Department of Hematology and Cell Therapy, San Bortolo Hospital, Ospedale San Bortolo, Via Rodolfi 37, 36100 Vicenza, Italy. carlovisco@hotmail.com
Key Words	Hepatitis C virus; Non-Hodgkin lymphoma; Liver; Toxicity; Diffuse large B-cell lymphoma; Rituximab; Cyclophosphamide; Hydroxydaunorubicin; Vincristine; Prednisolone; Immuno-chemotherapy; Antiviral treatment
Core Tip	Patients with hepatitis C virus-positive diffuse large B-cell lymphoma should be managed in a multidisciplinary setting. Initial evaluation of liver status and comorbidities is essential to establish if the patient is candidate to curative approaches. Unless contraindicated by adverse clinical conditions, patients should be treated with standard immuno-chemotherapy. Concomitant hepatitis B virus infection and liver failure or cirrhosis confer a significantly higher risk of viral reactivation or therapy related complications. These patients should be managed cautiously and treated with less intense approaches at least for the initial cycles. Antiviral treatment should be considered after the end of immuno-chemotherapy, when lymphoma remission has been achieved.
Publish Date	2014-08-29 11:57
Citation	Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment. World J Gastroenterol 2014; 20(32): 11054-11061
URL	http://www.wjgnet.com/1007-9327/full/v20/i32/11054.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i32.11054

Full Article (PDF)	WJG-20-11054.pdf
Full Article (Word)	WJG-20-11054.doc
Manuscript File	8307-Review.docx
Answering Reviewers	8307-Answering reviewers.pdf
Copyright License Agreement	8307-Copyright assignment.pdf
Peer-review Report	8307-Peer reviews.pdf
Scientific Misconduct Check	8307-CrossCheck.jpg
Scientific Editor Work List	8307-Scientific editor work list.pdf